Since continued AR activity is a primary factor in CRPC progression and treatment resistance, especially to drugs like enzalutamide, restoring NXTAR expression through genetic methods or small molecules like the ACK1/TNK2 inhibitor (R)-9b has shown success in reducing AR/AR-V7 levels and shrinking drug-resistant prostate tumors in preclinical studies [59]. This evidence concerns the gene AR and prostate neoplasm.